Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo

European Journal of Pharmacology

Volumn 327, Issue 1, 1997, Pages 57-63

  Fujimura, Masaki ^a   Kita, Toshiyuki ^a   Myou, Shigeharu ^a   Tachibana, Hideki ^a   Matsuda, Tamotsu ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti allergic effect; Bronchodilator effect; Guinea pig; Phosphodiesterase I IV inhibitor; Phosphodiesterase III inhibitor

Indexed keywords

CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL MODEL; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030947240     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)89678-1     Document Type: Article

References (35)

1. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:1990;150.
2. Boer J., Philpott A.J., Amsterdam G.M., Shahid M., Zaagsma J., Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isozymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106:1992;1028.
3. Bourne H.R., Lichtenstein L.M., Melmon K.L., Henney C.S., Weinstein Y., Shearer G.M. Modulation of inflammation and immunity by cyclic AMP. Science. 184:1974;19.
4. Fujimura M. Inhibitory effects of steroids on slow-reacting substance of anaphylaxis (SRS-A) mediated bronchoconstriction in the guinea pig in vivo. Jpn. J. Allergol. 32:1983;365.
5. Fujimura M., Koshino K., Ishizaki T., Minami S., Saga T., Miyabo S. The inhibitory effect of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′) on SRS-A mediated bronchoconstriction in the guinea pig in vivo. Allergy. 40:1985;98.
6. Fujimura M., Sakamoto S., Nishi K., Saito M., Miyake Y., Matsuda T. Inhibitory effect of inhaled procaterol on anaphylactic bronchoconstriction and thromboxane production in guinea pigs. Clin. Exp. Allergy. 21:1991;189.
7. Fujimura M., Kamio Y., Saito M., Hashimoto T., Matsuda T. Bronchodilator and bronchoprotective effect of cilostazol in humans in vivo. Am. J. Respir. Crit. Care Med. 151:1995;222.
8. Giembycz M.A., Raeburn D. Putative substrates for cyclic nucleotide-dependent protein kinases and the control of airway smooth muscle tone. J. Auton. Pharmacol. 11:1991;365.
9. Howell R.E., Sickels B.D., Woeppel S.L. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitor in guinea pigs. J. Pharmacol. Exp. Ther. 264:1993;609.
10. Jenne, J.W., 1987. Physiology and pharmacodynamics of the zanthines. In: Jenne, J.W., Murphy, S. (Eds.), Drug Therapy for Asthma: Research and Clinical Practice (Lung Biology in Health and Disease Series). Marcel Dekker, New York, NY, p. 297.
11. Jones T., Masson P., Hamel R., Brunet G., Holme G., Girard Y., Larue M., Rokach J. Biological activity of leukotriene sulfones on respiratory tissues. Prostaglandins. 24:1982;279.
12. Konzett H., Rossler R. Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur. Arch. Exp. Pathol. Pharmakol. 195:1940;71.
13. Kuehl F.A., Zanetti M.E., Soderman D.D., Miller D.K., Ham E.A. Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. Am. Rev. Respir. Dis. 136:1987;210.
14. Lagente V., Moodley I., Perrin S., Mottin G., Junien J.L. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophilic infiltration in the guinea-pig lung. Eur. J. Pharmacol. 255:1994;253.
15. Lagente V., Pruniaux M.P., Junien J.L., Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 151:1995;1720.
16. 2 receptor. Nature. 244:1973;287.
17. Manabe H., Ohnuma K., Ichimura M., Kawakita T., Suzuki F., Ohmori K. Pharmacological properties of a new bronchodilator, KF19514. Jpn. J. Pharmacol. 67(Suppl.):1995;24.
18. Minami S., Okafuji K., Saga T., Fujimura M., Kanamori K., Miyabo S., Hattori K., Kawai K. A new quantitative inhalation apparatus for small animals. Jpn. J. Chest Dis. 21:1983;252.
19. 2 and 5-lipoxygenase products. Juzen Igaku Zasshi. 103:1994;530.
20. Nicholson C.D., Challiss R.A.J., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12:1991;19.
21. Persson C.G.A., Andersson K.E., Kjellin G. Effects of enprofylline and theophylline may show the role of adenosine. Life Sci. 38:1986;1057.
22. Plaut M., Marone G., Thomas L.L., Lichtenstein L.M. Cyclic nucleotides in immune responses and allergy. Adv. Cycl. Nucleotide Res. 12:1980;161.
23. Santives T., Roska A.K., Hensley G.T., Moore V.L., Fink J.N., Abramoff P. Immunologically induced lung disease in guinea pigs. J. Allergy Clin. Immunol. 57:1976;582.
24. Sturm R.S., Osborn M.C., Heaslip R.J. The effect of phosphodiesterase inhibitors on pulmonary inflammatory cell influx in ovalbumin-sensitized guinea pigs. J. Cell Biochem. 14C(Suppl.):1990;337.
25. Tani T., Sakurai K., Kimura Y., Ishikawa T., Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors: effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv. Second Messenger Phosphoprotein Res. 25:1992;215.
26. Teixeira M.M., Rossi A.G., Williams T.J., Hellewell P.G. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. J. Pharmacol. 112:1994;332.
27. Thompson W.J. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther. 51:1991;13.
28. Torphy, T.J., Hay, D.W.P., 1990. Biochemical regulation of airway smooth-muscle tone: an overview. In: Townley, R.G., Agrawal, D.K. (Eds.), Airway Smooth Muscle: Modulation of Receptors and Response. CRC Press, Boston, MA, p. 39.
29. Torphy T.J., Burman M., Huang L.B.F., Tucker S.S. Inhibition of the low Km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 9836: mechanical and biochemical responses. J. Pharmacol. Exp. Ther. 246:1988;843.
30. Torphy T.J., Livi G.P., Balcarek J.M., White J.R., Chilton F.H., Undem B.J. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv. Second Messenger Phosphoprotein Res. 25:1992;289.
31. Torphy T.J., Undem B.J., Cieslinski L.B., Luttmann M.A., Reeves M.L., Hay D.W.P. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 265:1993;1213.
32. Underwood D.C., Osborn R.R., Novak L.B., Matthews J.K., Newsholme S.J., Undem B.J., Hand J.M., Torphy T.J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266:1993;306.
33. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W.P., Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270:1994;250.
34. Weishaar R.E., Cain M.H., Bristol J.A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phospho-diesterase and the potential for drug selectivity. J. Med. Chem. 28:1985;537.
35. Yasunaga K., Mase K. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneim.-Forsch./Drug Res. 35:1985;1189.